In This Article:
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.
Top 5 Upgrades:
-
UBS upgraded Sunrun (RUN) to Buy from Neutral with a price target of $17, up from $14. Sunrun looks attractive with the shares trading near all-time low multiples despite emerging positive trends like its California market share has nearly doubled to 22% over the past year, the analyst tells investors in a research note.
-
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for upward estimate revisions on lenacapavir for pre-exposure prophylaxis and further multiple expansion as the company makes progress with its next-gen HIV treatment strategy.
-
Goldman Sachs upgraded NXP Semiconductors (NXPI) to Buy from Neutral with a price target of $257, down from $260, implying 23% potential upside. Although forward visibility, particularly across the automotive and industrial businesses, remains limited, Goldman does not expect a round of estimate cuts ahead of and after NXP's Q4 earnings report on February 3, the analyst tells investors in a research note.
-
Piper Sandler upgraded Nike (NKE) to Overweight from Neutral with a price target of $90, up from $72. The firm says that while it is "possibly early with this call," Nike CEO Elliott Hill's "intensified urgency" to clean up the marketplace should translate to a more visible recovery story entering fiscal 2026 while buy-side sentiment remains negative.
-
Monness Crespi upgraded Pinterest (PINS) to Buy from Neutral with a $40 price target. In 2024, Pinterest executed well on its strategic initiatives and further transformed the platform, says the analyst, who believes Pinterest has "made great strides" in bolstering advertiser support, enhancing the user experience, and collaborating with third-party ad partners.
Top 5 Downgrades:
-
Goldman Sachs downgraded AMD (AMD) to Neutral from Buy with a price target of $129, down from $175, representing 6% potential upside from current levels. The firm remains constructive on the company's ability to take share from Intel (INTC) in x86-based compute across PCs and traditional servers, but is increasingly concerned that the rise of Arm-based (ARM) custom central processing units, coupled with the competitive intensity in accelerated computing, will weigh on AMD's revenue growth relative to peers.
-
KeyBanc last night downgraded AppFolio (APPF) to Sector Weight from Overweight without a price target. With limited near-term catalysts and the shares fairly valued on a free cash flow basis, the stock's current risk/reward is more balanced, the analyst tells investors in a research note.
-
JPMorgan downgraded Joby Aviation (JOBY) and Archer Aviation (ACHR) to Underweight from Neutral. While the stocks are"marginally more de-risked" than the 2023 period, the shares are trading as though type certification has already been successfully completed, the analyst tells investors in a research note.
-
RBC Capital downgraded IGM Biosciences (IGMS) to Sector Perform from Outperform with a price target of $1.50, down from $20. Following the company's decision to discontinue its primary value-driving IgM-based bispecific autoimmune clinical pipeline, reduce workforce by 73%, and seek strategic alternatives, RBC expects sharp downside for shares and expects the stock to settle in around anticipated cash levels one year out. IGM was also downgraded at Morgan Stanley, Stifel, and BMO Capital.
-
Citi downgraded Hims & Hers (HIMS) to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the company's GLP-1 revenue stream.